Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí, A. Ruíz, Manuel Ramos, Encarna Adrover, Álvaro Rodríguez-Lescure, Lourdes Calvo, Concepción Fernández‐Chacón, Montserrat Roset,

Annals of Oncology · 2006 · 204 citations · 17 references

DOIFull text

Open access

Concepts

References

17